By contrast, its expression was negatively correlated with the stromal and immune score in pancreatic adenocarcinoma, bladder urothelial carcinoma, and stomach adenocarcinoma, which suggested that with an increase in the stromal and immune score, FOXQ1 expression was decreased (Figure 9). This evidence concerns the gene FOXQ1 and pancreatic adenocarcinoma.